share_log

HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target

Benzinga ·  May 7 08:06

HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment